| 4 | 0 | 15 |
| 下载次数 | 被引频次 | 阅读次数 |
目的：通过评估前列腺癌(PCa)患者组织中E2F1的表达与血清中胆固醇的水平，探讨其可能存在的机制。方法：选取2024年1月至2025年6月佳木斯大学附属第一医院收治的PCa患者35例为PCa患者组，另选取同期体检的健康志愿者35例为健康对照组，分别测量其血清甘油三酯(TG)、载脂蛋白(ApoB)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)水平；Western blot、免疫组化、qRT-PCR检测PCa组织与癌旁组织中E2F1表达。结果：PCa患者癌组织E2F1表达水平显著高于癌旁组织(P<0.05);PCa患者组血清TG、ApoB、LDL-C水平高于健康组(P<0.05),而血清HDL-C水平显著低于健康组(P<0.05)。结论：E2F1可能通过调节脂肪细胞分化和脂肪生成促进前列腺癌的进展，进而推动肿瘤生长。
Abstract：Objective: To explore the possible mechanism by evaluating the expression of E2F1 in prostate cancer tissues and the level of serum cholesterol in prostate cancer patients. Methods: 35 prostate cancer patients admitted to The First Affiliated Hospital of Jiamusi University from January 2024 to June 2025 were selected. Additionally, 35 healthy volunteers who underwent physical examinations in our hospital during the same period were selected as the healthy control group. The levels of serum triglycerides(TG), apolipoprotein(ApoB), low-density lipoprotein(LDL-C), and high-density lipoprotein(HDL-C) were measured respectively. Western blot, immunohistochemistry, and qRT-PCR were used to detect the expression of E2F1 in prostate cancer tissues and adjacent tissues. Results: The expression level of E2F1 in cancer tissues of prostate cancer patients was significantly higher than that in adjacent tissues(P<0.05). The levels of serum TG, ApoB, and LDL-C in the prostate cancer patient group were higher than those in the healthy group(P<0.05), while the serum HDL-C level was significantly lower than that in the healthy group(P<0.05). Conclusion: E2F1 may promote the progression of prostate cancer by regulating adipocyte differentiation and lipogenesis, thereby driving tumor growth.
[1]DONG X,ZHANG Q,HAO J,et al.Large multicohort study reveals a prostate cancer susceptibility allele at 5p15 regulating TERT via androgen signaling-orchestrated chromatin binding of E2F1 and MYC[J].Front Oncol,2021,11:754206.
[2]BERGENGREN O,PEKALA KR,MATSOUKAS K,et al.2022 update on prostate cancer epidemiology and risk factors-a systematic review[J].Eur Urol,2023,84(2):191-206.
[3]JAMES ND,TANNOCK I,NDOW J,et al.The lancet commission on prostate cancer:planning for the surge in cases[J].Lancet,2024,403(10437):1683-1722.
[4]LOWRANCE W,DREICER R,JARRARD DF,et al.Updates to advanced prostate cancer:AUA/SUO guideline (2023)[J].J Urol,2023,209(6):1082-1090.
[5]ZHOU X,MAO J,AI J,et al.Identification of plasma lipid biomarkers for prostate cancer by lipidomics and bioinformatics[J]..PLoS One,2012,7(11):e48889.
[6]ZHOU Y,NAKAJIMA R,SHIRASAWA M,et al.Distinct regulation of the ARF and TAp73 tumor suppressor genes by the transcription factor E2F1 enables discrimination of cancer cells from normal growing cells[J].Cells,2026,15(1):90.
[7]XIONG K,WANG G,PENG T,et al.The cholesterol esterification inhibitor avasimibe suppresses tumour proliferation and metastasis via the E2F-1 signalling pathway in prostate cancer[J].Cancer Cell Int,2021,21(1):461.
[8]LI X,SUN Z,ZENG R,et al.Diet-metabolism-transcription axis modulates the sensitivity to CDK4/6 inhibitors through RB1 in prostate cancer[J].Cell Rep,2025,44(11):116530.
[9]ALI ETO,MOHAMED NS,SIDDIG EE,et al.Evaluating cholesterol de novo synthesis biomarkers:a systematic review and meta-analysis of cancer prognosis and clinical outcomes[J].BMC Cancer,2025,25(1):1208.
[10]ALBERTO M,YIM A,LAWRENTSCHUK N,et al.Dysfunctional lipid metabolism-the basis for how genetic abnormalities express the phenotype of aggressive prostate cancer[J].Cancers (Basel),2023,15(2):341.
[11]JING Z,LIU Q,HE X,et al.NCAPD3 enhances warburg effect through c-myc and E2F1 and promotes the occurrence and progression of colorectal cancer[J].J Exp Clin Cancer Res,2022,41(1):198.
[12]CHEN S,HE Z,PENG T,et al.PRR11 promotes ccRCC tumorigenesis by regulating E2F1 stability[J].JCI Insight,2021,6(19).
[13]GONZALEZ-ROMERO F,MESTRE D,AURREKOETXEA I,et al.E2F1 and E2F2-mediated repression of CPT2 establishes a lipid-rich tumor-promoting environment[J].Cancer Res,2021,81(11):2874-2887.
[14]SHEN D,GAO Y,HUANG Q,et al.E2F1 promotes proliferation and metastasis of clear cell renal cell carcinoma via activation of SREBP1-dependent fatty acid biosynthesis[J].Cancer Lett,2021,514:48-62.
[15]REN Z,KANG W,WANG L,et al.E2F1 renders prostate cancer cell resistant to ICAM-1 mediated antitumor immunity by NF-kappaB modulation[J].Mol Cancer,2014,13:84.
[16]GUO K,LIU C,SHI J,et al.HMMR promotes prostate cancer proliferation and metastasis via AURKA/mTORC2/E2F1 positive feedback loop[J].Cell Death Discov,2023,9(1):48.
[17]HRYNIEWICZ-JANKOWSKA A,AUGOFF K,SIKORSKI AF.The role of cholesterol and cholesterol-driven membrane raft domains in prostate cancer[J].Exp Biol Med (Maywood),2019,244(13):1053-1061.
[18]RAFTOPULOS NL,WASHAYA TC,NIEDERPRüM A,et al.Prostate cancer cell proliferation is influenced by LDL-cholesterol availability and cholesteryl ester turnover[J].Cancer Metab,2022,10(1):1.
[19]CROWLEY F,STERPI M,BUCKLEY C,et al.A review of the pathophysiological mechanisms underlying castration-resistant prostate cancer[J].Res Rep Urol,2021,13:457-472.
[20]孟焱，王丽娜.老年前列腺癌根治术患者院外延续性护理服务需求及影响因素分析[J].黑龙江医药科学，2025,48(1):53-54,57.
[21]辛华，王莉，刘丽秋，等.调强放疗联合内分泌治疗对局部晚期前列腺癌患者T淋巴细胞亚群及肿瘤标志物的控制分析[J].黑龙江医药科学，2022,45(5):13-14.
[22]牟洪香，王莉，辛华，等.尿肌氨酸检测对前列腺癌早期诊断的价值及准确性分析[J].黑龙江医药科学，2020,43(3):98-99,103.
[23]SUH J,SHIN TJ,YOU D,et al.The association between serum lipid profile and the prostate cancer risk and aggressiveness[J].Front Oncol,2023,13:1113226.
[24]WASIM S,LEE SY,KIM J.Complexities of prostate cancer[J].Int J Mol Sci,2022,23(22):14257.
[25]BISWAS P,DATTA C,RATHI P,et al.Fatty acids and their lipid mediators in the induction of cellular apoptosis in cancer cells[J].Prostaglandins Other Lipid Mediat,2022,160:106637.
基本信息:
中图分类号:R737.25
引用信息:
[1]王李鸣,崔国利,陈雨菲,等.前列腺癌患者组织中E2F1与血清胆固醇的表达分析[J].黑龙江医药科学,2026,49(08):5-8.
基金信息:
黑龙江省自然科学基金项目,编号：PL2024H017
2026-08-10
2026-08-10